Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 4:11:754687.
doi: 10.3389/fonc.2021.754687. eCollection 2021.

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Ben George  1 , Matthew Kent  2 , Andy Surinach  2 , Neil Lamarre  2 , Paul Cockrum  3
Affiliations

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Ben George et al. Front Oncol. .

Abstract

Background: Pancreatic cancer is expected to be the third deadliest cancer in the US in 2021. Evaluation of treatment response in patients with mPDAC necessitates scheduled clinical and radiographic assessments along with monitoring serum CA 19-9 levels. Currently available single-institution data examining the importance of CA 19-9 monitoring cannot be generalized to real-world settings. We investigated the impact of serum CA 19-9 monitoring and its association with clinical outcomes in patients with mPDAC in a population-based setting.

Methods: Data were extracted from the Flatiron Health electronic health record (EHR)-derived de-identified database for patients diagnosed with mPDAC between January 1, 2015, and June 30, 2020. Serum CA 19-9 levels at baseline - defined as the values obtained ≤ 60 days prior to treatment initiation - and during treatment were extracted. CA 19-9 levels > 40 IU/mL were considered elevated. Survival outcomes were compared based on testing frequency, baseline CA 19-9 levels, and change in CA 19-9.

Results: 6,118 patients with mPDAC who received treatment were included in the analysis. The median age at diagnosis was 68 years (IQR: 61-75). Patients with normal baseline CA 19-9 experienced longer median survival than patients with elevated levels [1L: 8.8 months (95% CI: 7.9 - 10) vs. 7.2 months (6.8 - 7.5), p < 0.001; 2L: 7.2 months (6.1 - 9.2) vs. 5.2 months (4.9 - 5.6), p < 0.001; 3L: 6.1 months (5.4 - 9.1) vs. 3.9 months (3.4 - 4.3), p < 0.001]. Patients with decreasing/stable CA 19-9 during treatment experienced longer survival than patients who experienced an increase in CA 19-9 levels [1L: 10.9 months (10.5 - 11.3) vs. 5.4 months (5.1 - 5.9), p < 0.0001; 2L: 8.2 months (7.7 - 8.5) vs. 4.3 months (4.1 - 4.7), p < 0.001; 3L: 7.5 months (6.6 - 9.2) vs. 3.7 months (3.4 - 4.3), p < 0.001].

Conclusions: In one of the largest, contemporary, real-world studies of patients with mPDAC, elevated CA 19-9 level at treatment initiation demonstrated a prognostic impact. Routine serial monitoring of CA 19-9 levels during treatment may be warranted, in addition to clinical and radiographic assessment, and may translate into better patient outcomes. Further validation studies are needed to understand the generalizability of these results.

Keywords: CA 19-9; chemotherapy; metastatic pancreatic cancer; overall survival; prognostic factor.

PubMed Disclaimer

Conflict of interest statement

BG reports a consulting/advisory relationship with Ipsen. MK, AS, and NL are employees of Genesis Research which receives funding for consulting services from Ipsen. PC is an employee of and has stock in Ipsen. This study was sponsored by Ipsen. The sponsor had the following involvement in the study: design of the study, analysis, and interpretation as well as review of the manuscript.

Figures

Figure 1
Figure 1
Overall survival by Baseline Carbohydrate Antigen 19-9.
Figure 2
Figure 2
Overall Survival by Carbohydrate Antigen 19-9 Testing Status among patients treated in first line.
Figure 3
Figure 3
Overall Survival by Carbohydrate Antigen 19-9 Testing Status among patients treated in second line.
Figure 4
Figure 4
Overall Survival by Carbohydrate Antigen 19-9 Testing Status among patients treated in third line.
See this image and copyright information in PMC

References

    1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. , eds. SEER Cancer Statistics Review (CSR) 1975-2017. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2017/.
    1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol (2019) 10(1):10–27. doi: 10.14740/wjon1166 - DOI - PMC - PubMed
    1. Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, et al. . An Update on Treatment Options for Pancreatic Adenocarcinoma. Ther Adv Med Oncol (2019) 11:1758835919875568. doi: 10.1177/1758835919875568 - DOI - PMC - PubMed
    1. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. . Cancer of the Pancreas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol (2015) 26(Suppl 5):v56–68. doi: 10.1093/annonc/mdv295 - DOI - PubMed
    1. Dell’Aquila E, Fulgenzi CAM, Minelli A, Citarella F, Stellato M, Pantano F, et al. . Prognostic and Predictive Factors in Pancreatic Cancer. Oncotarget (2020) 11(10):924–41. doi: 10.18632/oncotarget.27518 - DOI - PMC - PubMed

LinkOut - more resources